Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.68 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392550 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL29354058 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL675746 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL1236293 | 0.89 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL11974531 | 0.89 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL1236290 | 0.89 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL392628 | 0.87 | HDAC3 (0.77) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL11984101 | 0.86 | HDAC1 (0.76) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL25049810 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL11886047 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000031-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-8524762-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | claimed |
| EP-1414428-B1 | HISTONE DEACETYLASE ENZYME-INHIBITING DERIVATIVES OF HYDROXAMIC ACID AS NEW CYTOKINE SYNTHESIS-INHIBITING ANTI-INFLAMMATORY DRUGS | ITALFARMACO SPA (IT) | 2009-07-01 | — | — | EP | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
| US-20040157930-A1 | Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs | ITALFARMACO S.P.A. (IT) | 2004-08-12 | — | — | US | claimed |
| EP-1414428-A1 | HISTONE DEACETYLASE ENZYME-INHIBITING DERIVATIVES OF HYDROXAMIC ACID AS NEW CYTOKINE SYNTHESIS-INHIBITING ANTI-INFLAMMATORY DRUGS | ITALFARMACO S.p.A. (IT) | 2004-05-06 | — | — | EP | claimed |
| WO-2003013493-A1 | HISTONE DEACETYLASE ENZYME-INHIBITING DERIVATIVES OF HYDROXAMIC ACID AS NEW CYTOKINE SYNTHESIS-INHIBITING ANTI-INFLAMMATORY DRUGS | ITALFARMACO S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-11357748-B2 | Methods for treating mendelian disorders of the epigenetic machinery | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3024926-B1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
| EP-1414428-A1 | HISTONE DEACETYLASE ENZYME-INHIBITING DERIVATIVES OF HYDROXAMIC ACID AS NEW CYTOKINE SYNTHESIS-INHIBITING ANTI-INFLAMMATORY DRUGS | ITALFARMACO S.p.A. (IT) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003013493-A1 | HISTONE DEACETYLASE ENZYME-INHIBITING DERIVATIVES OF HYDROXAMIC ACID AS NEW CYTOKINE SYNTHESIS-INHIBITING ANTI-INFLAMMATORY DRUGS | ITALFARMACO S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC3 6/4885HDAC2 4/4885 |
| US-20040157930-A1 | Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs | HDAC1, HDAC2, HDAC5 | HDAC1 1/4885HDAC3 6/4885HDAC2 2/4885 |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC1 3/4885HDAC3 8/4885HDAC2 5/4885 |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | HDAC1 4012/4885HDAC3 3990/4885HDAC2 4253/4885 |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | HDAC1 1/4885HDAC3 9/4885HDAC2 8/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC1 464/4885HDAC3 418/4885HDAC2 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.